B+L/Novaliq Hope Miebo Can Stand Out In Crowded Dry Eye Field

Big Week For Bausch As Court Ruling Could Benefit Planned Spinoff

The companies got US FDA approval for the drug, which they said is the only approved medicine that targets tear evaporation rather than tear production, though its mechanism is not fully understood.

Bausch + Lomb and Novaliq announced the approval of Miebo in dry eye disease • Source: Shutterstock

Bausch + Lomb Corporation and Novaliq GmbH hope to stand out in the crowded field of dry eye disease (DED) with their newly US Food and Drug Administration-approved Miebo (perfluorohexyloctane) based on its mechanism of action and a unique claim of direct effect on tear evaporation.

The commercial effort could be helped by Bausch + Lomb parent company Bausch Health Companies Inc.’s victory in federal...